Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of Durvalumab in Combination With Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma-- DULECT2020-1 Trial

NCT04443322 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04443322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of Durvalumab in Combination With Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma-- DULECT2020-1 Trial
Lead sponsor
RenJi Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 19, 2020
Completion date
December 31, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver carcinoma, liver transplant; complications